netFormulary Dorset NHS
The Dorset Formulary has been developed in associations with
NHS Dorset Clinical Commissioning Group
Dorset County Hospital NHS Foundation Trust
Dorset Healthcare University NHS Foundation Trust
Poole Hospital NHS Foundation Trust
Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust
 
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Notes:

Updated in accordance with CDF and NICE guidance May 2018. For latest CDF list click here.

Chapter Links...
 Details...
08.02.04  Expand sub section  Other immunomodulating drugs
Aldesleukin (Proleukin®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Commissioned by NHS England for cancer, but not routinely. 
   
Canakinumab (Ilaris®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Commissioned by NHS England as per Cryopyrin Associated Periodic Syndrome service specification.

Not routinely commissioned by NHS England for juvenile arthritis - see NICE TA302. 
Link  NICE TA302: terminated TA on canakinumab for treating juvenile arthritis
   
Interferon Alfa (IntronA®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Commissioned by NHS England for hepatitis B (TA96) and C (TA75).

 
Link  NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C.
Link  NICE TA96: Adefovir and peginteferon alfa-2a for the treatment of chronic hepatitis B.
   
Mifamurtide (Mepact ®)
View adult BNF View childrens BNF  Track Changes
Formulary
Red
 
Link  NICE TA235: Osteosarcoma - mifamurtide
   
Peginterferon Alfa (Pegasys® ; ViraferonPeg® )
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Commissioned by NHS England (for Hepatitis B and C), as per NICE TA75, TA96, TA106, TA200, TA300 and CG165.

 
Link  NICE CG 165: Hepatitis B (chronic) updates and replaces TA96
Link  NICE TA106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C
Link  NICE TA200: Hepatitis C - peginterferon alfa & ribavirin
Link  NICE TA300: Hepatitis C (children and young people) - peginterferon alfa and ribavirin
Link  NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
Link  NICE TA96: adefovir, dipoxivin and peginterferon alfa2a for chronic hepatitis B
   
08.02.04  Expand sub section  Multiple Sclerosis
Alemtuzumab (Lemtrada®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned by NHS England for treatment multiple sclerosis in accordance with NICE TA312.

Commissioned for two treatment courses only as per marketing authorisation. Any subsequent courses by IFR only.

 
Link  NICE TA312: Alemtuzumab for treating relapsing‑remitting multiple sclerosis
   
Cytotoxic Drug Cladribine (Mavenclad®)
(Multiple Sclerosis)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned by NHS England for treatment of highly active relapsing multiple sclerosis at approved centres in accordance with NICE TA493.

 
Link  Mavenclad® Prescriber’s Guide
Link  NICE TA493: Cladribine tablets for treating relapsing–remitting multiple sclerosis
   
Dimethyl fumarate (Tecfidera®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned by NHS England for treatment of MS at approved centres in accordance with NICE TA320.

 
Link  NICE TA320: Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis
   
Fingolimod (Gilenya®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned by NHS England for treatment of MS at approved centres in accordance with NICE TA254.

 
Link  NHS England policy: D04/P/b
Link  NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis
   
Glatiramer Acetate (Copaxone®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned by NHS England for treatment of MS at approved centres in accordance with NICE TA32.

 
Link  NHS England Policy: D04/P/b
Link  NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
   
Interferon Beta-1a & Interferon Beta 1-b (Avonex®, Rebif®, Extavia®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned by NHS England (for Multiple sclerosis) in accordance with NICE TA527 and Department of Health guidance contained in health service circular 2002/004. See NHS England Policy: D04/P/b

Note: Betaferon® is not recommended as per NICE TA527.

 
Link  DSU vol 8, iss 3, Oct 2014:A1.Interferon-beta: risk of thrombotic microangiopathy and risk of nephrotic syndrome
Link  NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
   
Natalizumab (Tysabri®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned by NHS England for treatment of MS at approved centres in accordance with NICE TA127.

 
Link  NHS England Policy: D04/P/b
Link  NICE TA127: Natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis
   
Peginterferon beta-1a (Plegridy®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned by NHS England for Multiple Sclerosis as per SSC1534: Multiple Sclerosis: First line disease modifying agents

 
Link  SSC1534: Multiple Sclerosis: First line disease modifying agents
   
Teriflunomide (Aubagio®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned by NHS England for treatment of MS at approved centres in accordance with NICE TA303.

Not recommended in highly active or rapidly evolving severe relapsing-remitting MS as per NICE TA303.

 
Link  NHS England policy: D04/P/b
Link  NICE TA303: Teriflunomide for treating relapsing-remitting MS
   
08.02.04  Expand sub section  BCG bladder instillation
BCG bladder instillation (ImmuCyst®)
View adult BNF View SPC online  Track Changes
Formulary
Red
Bacillus Calmette-Guérin

 
   
BCG bladder instillation (OncoTICE®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
1st line at RBCH 
Link  Letter sent to HCPs Aug 2014: Supply update: OncoTICE (BCG 12.5mg per vial)
   
08.02.04  Expand sub section  Lenalidomide, pomalidomide, and thalidomide
Thalidomide (Thalidomide Celgene®)
View adult BNF View SPC online  Track Changes
First Choice
Red
High Cost Medicine
NHS England

Commissioned by NHS England as per NICE TA228. First line agent for multiple myeloma.

 
Lenalidomide (Revlimid®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England

Commissioned by NHS England in line with NICE TA171 and TA322.

 
Link  NICE TA171: lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy
Link  NICE TA322: Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality
   
Pomalidomide (Imnovid®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

Commissioned by NHS England in line with NICE TA427.

 
Link  NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib
   
 ....
 Non Formulary Items
Daclizumab  (Zinbryta®)

View adult BNF View SPC online Track Changes
Non Formulary
High Cost Medicine
NHS England
BlueTeq

On 6 March 2018, the European Medicines Agency (EMA) recommended the immediate suspension and recall of daclizumb.

No new patients should start treatment with Zinbryta. Healthcare professionals should immediately contact patients currently being treated with Zinbryta and should stop their treatment and consider alternatives. Patients stopping treatment must be followed up for at least 6 months.

See link below for further detail.

Link  EMA license suspension - March 2018
Link  EMA restrictions of daclizumab
Link  Letter to professionals July 2017: Zinbryta (Daclizumab) restrictions of use in view of fatal fulminant liver failure
Link  Zinbryta (daclizumab beta): Marketing authorisation suspended in the European Union
 
Fampridine

View adult BNF View childrens BNF
Non Formulary
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Green

May be initiated, stabilised and maintained in primary, secondary or tertiary care  

Amber

Amber drug - without shared care  

Amber SCG

Amber drug - with shared care guideline  

Red

For secondary or tertiary care initiation and long-term maintenance of prescribing  

Black

Not recommended  

netFormulary